Efficacy and safety of pemafibrate in high risk patients with coronary artery disease - PEBE Trial

Department of Cardiology, Iwate Prefectural Centgral Hospital0 个研究点目标入组 60 人开始时间: 2022年5月13日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The %Change in TG and Apo A-I levels was significantly greater with pemafibrate than with bezafibrate (-46.1% vs. -34.7%, p<0.001; 9.2% vs. 5.7%, p=0.018, respectively). %Change in HDL-C levels was not significantly different between the two treatments. %Change in liver enzyme levels was markedly decreased with pemafibrate than with bezafibrate.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 75years-old（—）
性别: All

入选标准

未提供

排除标准

•1.patients who required additional medication for dyslipidemia during the study period 2.fasting serum TG levels of over than 1000 mg/dl 3.type 1 diabetes mellitus or uncontrolled type 2 DM (HbA1c level of over than 8.5%) 4.familiar hypercholesterolemia 5.chronic kidney disease showing a serum creatinine level of over than 1.5 mg/dL 6.history or complication of gallbladder disease, cholelithiasis, pancreatitis, and malignant tumor 7.aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation to a level more than two times the upper limit of normal (ULN) range 8.uncontrolled hypertension (systolic blood pressure BP ofover tahn 160 mmHg or diastolic BP of over than 100 mmHg) 9.hemoglobin level of less than 12g/dL in men or less than 11 g/dL in women 11.recent myocardial infarction or cerebrovascular disorder within 3 months before the study 12.hospitalization for worsening heart failure within 3 months 13.use of ezetimibe and supplements containing eicosapentaenoic acid, and/or docosahexaenoic acid within 3 months before the study. Patients were also prohibited from using agents that affect lipid metabolism,such as thiazolidinedione, insulin,oral corticosteroid, or protease inhibitor.

研究者

发起方

Department of Cardiology, Iwate Prefectural Centgral Hospital

相似试验

尚未招募

不适用

Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemiaprimary biliary cholangitis

JPRN-UMIN000039350Shinshu University Faculty of Medicine, Department of Gastroenterology60

终止

3 期

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)Type2 DiabetesDyslipidemia

NCT03071692Kowa Research Institute, Inc.10,544

Unknown

3 期

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With AtorvastatinMixed Hyperlipidemia

NCT01956201Chong Kun Dang Pharmaceutical476

招募中

Unknown

The efficacy and safety of the pemafibrate in subjects with dyslipidemia and severely decreased renal function; a prospective observational studyDyslipidemia, chronic kidney disease

JPRN-UMIN000053168Kushiro Red Cross Hospital60

已完成

4 期

The impact of pemafibrate on hypertriglyceridemia in patients with type 2 diabetes: A prospective cohort study.dyslipidemi

JPRN-UMIN000037385Hokkaido University Hospital650